133384-73-3

Upstream product

• 77-76-9 2,2-dimethoxy-propane 
• 82962-54-7 2,2-dimethyl-5-ethoxycarbonyl-1,3-dioxane 
• 51335-75-2 2,2-Dimethyl-1,3-dioxacyclohexane-5,5-dicarboxylic acid,diethyl ester 
• 4728-12-5 2,2-dimethyl-5-hydroxymethyl-1,3-dioxane 
• 98-59-9 p-toluenesulfonyl chloride 
• 104-15-4 toluene-4-sulfonic acid 

Downstream Products

• 113002-29-2 R_S-1-methyl-2-(2,2-dimethyl-1,2-dioxolanyl)-2-p-tolylsulfinyl-1-ethanone 
• 1093988-35-2 4-{[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]oxy}benzohydrazide 
• 1093988-36-3 3-chloro-5-[(6-chloro-3-{[5-(4-{[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]oxy}phenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 
• 1093988-34-1 methyl 4-{[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]oxy}benzoate 
• 97827-17-3 5-iodomethyl-2,2-dimethyl-1,3-dioxane 
• 133384-72-2 2,2-dimethyl-5-ethoxymethyl-1,3-dioxane 

Relevant academic research and scientific papers

ARYL GLYCOSIDE COMPOUND, PREPARATION METHOD AND USE THEREOF

Disclosed are an aryl glycoside compound as represented by formula I or formular I′, a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential.

ARYL GLYCOSIDE COMPOUND, PREPARATION METHOD AND USE THEREOF

Disclosed are an aryl glycoside compound as represented by formula I or formular I', a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof. The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential.

DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS

The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF.

CATIONIC LIPIDS AND USES THEREOF

Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

Synthesis of cluster mannosides carrying a photolabile diazirine group

We are investigating the mechanisms underlying the carbohydrate-specific adhesion of bacteria such as Escherichia coli to the glycocalyx of their potential host cells. E. coli possess protein appendages, which are called type 1 fimbriae. Part of type 1 fimbriae is a protein named FimH, which is a mannose-specific lectin. We wish to use photoaffinity labeling to elucidate mannose binding sites on FimH. Thus we report the synthesis of di- and trivalent cluster mannosides, which carry a photolabile diazirine group. The diazirine group was introduced by a convergent approach using thiourea bridging (products 6, 13, 17, and 27) or in a divergent synthesis leading to the divalent cluster mannoside 31. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.

Synthetic studies on spiroketal natural products. IV. A stereoselective synthesis of (3S,5S,6R,9R,R(S))-3-benzyloxymethyl-9-hydroxymethyl-5-(p-tolyl)sulfin yl-1,7-dioxaspiro[5.5]undecane, a key intermediate for talaromycins

A dioxaspiro compound (4), a common intermediate for the synthesis of talaromycin A (1) and (-)-talaromycin B (2), was synthesized by two routes utilizing two kinds of asymmetric recognition of prochiral 1,3-diols controlled by sulfinyl chirality, that is, firstly by acid promoted diastereoselective C-O bond fission of the bicyclic acetal (7) to give the dihydropyran derivative (6), which has an S-hydroxymethyl group at the C3-position (7 → 6), and secondly by diastereoselective intramolecular Michael addition of the diol (5), in which the three chiral centers at C5, C6, C9 were constructed in one step (5 → 4).

SYNTHESIS OF 5,5'-DIHYDROXYLEUCINE AND 4-FLUORO-5,5'-DIHYDROXYLEUCINE, THE REDUCTION PRODUCTS OF 4-CARBOXYGLUTAMIC AND 4-CARBOXY-4-FLUOROGLUTAMIC ACIDS

Schemes for the synthesis of 5,5'-dihydroxyleucine 3 and its 4-fluoro analog 7 involving the condensation of a suitable 'aminoacid moiety' with 2,2-dimethyl-5-iodomethyl-1,3-dioxane 15D or its fluoro analog 27A were tested.The anion of the ethyl N-diphenylmethylene-glycinate 25 gave better yields of 3 than the classical anion of diethyl acetamidomalonate.This strategy could not be successfully applied to the synthesis of 7, which could be prepared by reduction of a suitably protected 4-fluoro-4-carboxyglutamate with BMS.